Question 1

Purpose of the Test

Accepted Answer

Identifying specific genetic mutations within tumor cells. Guiding treatment decisions regarding Tyrosine Kinase Inhibitors (TKIs). Evaluating patient eligibility for modern targeted therapies.

Question 2

Target Groups

Accepted Answer

Patients diagnosed with Non-Small Cell Lung Cancer (NSCLC). Candidates for first-line targeted therapy protocols. Patients showing clinical resistance to standard treatments.

Question 3

Analyzed Mutations

Accepted Answer

Exon 19 deletions (most common sensitizing mutations). Exon 21 L858R point mutations. Resistance mutations such as T790M for treatment monitoring.

Precision Guide for Targeted Therapy - Epidermal Growth Factor Receptor (EGFR) Mutation Analysis